Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial

Punnee Pitisuttithum; Viravarn Luvira; Saranath Lawpoolsri; Sant Muangnoicharoen; Supitcha Kamolratanakul; Chaisith Sivakorn; Piengthong Narakorn; Somchaiya Surichan; Sumalee Prangpratanporn; Suttida Puksuriwong; Steven Lamola; Laina D Mercer; Rama Raghunandan; Weina Sun; Yonghong Liu; Juan Manuel Carreño; Rami Scharf; Weerapong Phumratanaprapin; Fatima Amanat; Luc Gagnon; Ching-Lin Hsieh; Ruangchai Kaweepornpoj; Sarwat Khan; Manjari Lal; Stephen McCroskery; Jason McLellan; Ignacio Mena; Marcia Meseck; Benjaluck Phonrat; Yupa Sabmee; Ratsamikorn Singchareon; Stefan Slamanig; Nava Suthepakul; Johnstone Tcheou; Narumon Thantamnu; Sompone Theerasurakarn; Steven Tran; Thanakrit Vilasmongkolchai; Jessica A White; Adolfo Garcia-Sastre; Peter Palese; Florian Krammer; Kittisak Poopipatpol; Ponthip Wirachwong; Richard Hjorth; Bruce L Innis

bioRxiv (2021) - Comments
doi: 10.1101/2021.09.17.21263758

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong, Steven Lamola, Laina D Mercer, Rama Raghunandan, Weina Sun, Yonghong Liu, Juan Manuel Carreño, Rami Scharf, Weerapong Phumratanaprapin, Fatima Amanat, Luc Gagnon